









Markets
/
Stocks
/
nasdaq-alks
/

Alkermes Plc

ALKS

32.890USD

+1.210+3.82%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

5.43BMarket Cap

16.03P/E TTM



Alkermes Plc

32.890

+1.210+3.82%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alkermes Plc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alkermes Plc's Score

Industry at a Glance

Industry Ranking

1 / 407

Overall Ranking

23 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 16 analysts

Buy

Current Rating

44.000

Target Price

+38.89%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Alkermes Plc Highlights

StrengthsRisks

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 40.10% year-on-year.

Overvalued

The company’s latest PE is 15.93, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 174.30M shares, decreasing 13.86% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 126.00K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.31.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 9.31, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 394.19M, representing a year-over-year increase of 4.24%, while its net profit experienced a year-over-year increase of 10.41%.

Score

Industry at a Glance

Previous score

9.31

Change



Financials

9.42

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.33

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Alkermes Plc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 7.59, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 15.93, which is 225.50% below the recent high of 51.86 and 311.26% above the recent low of -33.66.

Score

Industry at a Glance

Previous score

7.59

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 1/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for Alkermes Plc is 45.00, with a high of 56.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 16 analysts

Buy

Current Rating

44.000

Target Price

+38.89%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Alkermes Plc

ALKS

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 8.90, which is higher than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 36.67 and the support level at 28.76, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.34

Change

1.56

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.171

Buy

RSI(14)

64.545

Neutral

STOCH(KDJ)(9,3,3)

49.635

Neutral

ATR(14)

1.711

High Vlolatility

CCI(14)

134.144

Buy

Williams %R

43.337

Buy

TRIX(12,20)

0.119

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

31.240

Buy

MA10

30.989

Buy

MA20

31.032

Buy

MA50

29.803

Buy

MA100

29.064

Buy

MA200

30.338

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 105.56%, representing a quarter-over-quarter decrease of 2.70%. The largest institutional shareholder is The Vanguard, holding a total of 18.45M shares, representing 11.18% of shares outstanding, with 1.74% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

23.73M

-1.05%

The Vanguard Group, Inc.

Star Investors

18.45M

+1.60%

T. Rowe Price Associates, Inc.

Star Investors

9.86M

-15.13%

State Street Investment Management (US)

8.21M

+2.31%

Baker Bros. Advisors LP

6.41M

+42.99%

Renaissance Technologies LLC

Star Investors

5.81M

+1.24%

RTW Investments L.P.

4.68M

-31.99%

Geode Capital Management, L.L.C.

4.02M

+2.13%

American Century Investment Management, Inc.

3.66M

+5.53%

JP Morgan Asset Management

3.95M

-4.36%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 7.56, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.43. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.